spacer
home > ebr > spring 2019 > opportunities and challenges in cancer innovations
PUBLICATIONS
European Biopharmaceutical Review

Opportunities and Challenges in Cancer Innovations

Progress is being made in the long-standing battle to effectively treat and control cancer. The National Cancer Institute projects that nearly five million more US citizens are expected to survive cancer in 2026 than in 2016 (1). Therapeutic tools like nextgeneration sequencing and advances in immunotherapy are just two ways that fundamental scientific breakthroughs and innovative thinking are moving the potential for cancer treatment forward.

One of the most revolutionary breakthroughs in this new era is cell and gene therapy. At its most basic definition, gene therapy (also called human gene transfer) is the therapeutic delivery of nucleic acid into a patient’s cells as a drug to treat disease. According to The Journal of Gene Medicine, somewhere around 2,600 gene therapy clinical trials have been undertaken in 38 countries around the world as of November 2017 (2).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Ger Brophy is Executive Vice President of Biopharma Production at Avantor. In his current role, he is responsible for developing and implementing the company’s biopharma production and supporting the current and future needs of customers. Prior to joining Avantor, Ger held a variety of R&D, strategy, advanced systems, and business development positions in the healthcare space with GE Healthcare Life Sciences, GE Healthcare Medical Diagnostics, and Amersham for nearly 30 years. He earned a BSc in biotechnology as well as a PhD in molecular biology from Dublin City University, Ireland.
spacer
Dr Ger Brophy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Phillips-Medisize Enters Agreement with Global Pharmaceutical Company to Acquire Exclusive Ownership of Patents for an Innovative Mini-tablet Dispenser

HUDSON, WI – September 10, 2019 – Phillips-Medisize, a Molex company, announced today an agreement with a Global Pharmaceutical Company, where Phillips-Medisize acquired exclusive ownership of patents supporting an innovative mini-tablet dispenser to accommodate the varied and customized oral dispensing needs of patients.
More info >>

White Papers

Shipping with Active Packaging Containers: Three Pre-flight Decisions that Impact the Success of High-value Global Shipments

World Courier

It is the dead of winter in the northern hemisphere and the height of summer in the southern, with external temperature fluctuations exceeding 50 degrees. Flight delays have added precious days to the transport of your multi-million dollar shipment of blockbuster drug from South East Asia destined for Russia. In France, the roads are closed for days due to a monster snowstorm, with your irreplaceable shipment of investigational drugs stopped somewhere en route between Paris and the clinical trial site. Will all be lost, or can informed choices made before the shipment departs ensure product safety despite unforeseen circumstances?
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement